E-resources
PDF-
BONILLA-HERNAN, M. Gema; MIRANDA-CARUS, M. Eugenia; MARTIN-MOLA, Emilio
Rheumatology, 09/2011, Volume: 50, Issue: 9Journal Article
Orally available small molecule compounds have recently been developed for the treatment of RA, and inhibitors of signalling cascades, specifically inhibitors of kinases, have reached advanced stages of clinical development. The p38 mitogen-activated protein kinase blockers have shown poor clinical response despite encouraging preclinical data. In contrast, inhibitors of the non-receptor tyrosine kinases, spleen tyrosine kinase and janus kinase 3, have demonstrated a significant clinical efficacy together with an acceptable safety profile. We herein present a review on published preclinical and clinical data on these new drugs.
